These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 18803653)

  • 21. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.
    Wada-Isoe K; Kitayama M; Nakaso K; Nakashima K
    J Neurol Sci; 2007 Sep; 260(1-2):33-7. PubMed ID: 17459416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.
    Slaets S; Le Bastard N; Martin JJ; Sleegers K; Van Broeckhoven C; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2013; 36(4):759-67. PubMed ID: 23666174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
    Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
    Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.
    Sjögren M; Blomberg M; Jonsson M; Wahlund LO; Edman A; Lind K; Rosengren L; Blennow K; Wallin A
    J Neurosci Res; 2001 Nov; 66(3):510-6. PubMed ID: 11746370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.
    Kapaki EN; Paraskevas GP; Tzerakis NG; Sfagos C; Seretis A; Kararizou E; Vassilopoulos D
    Eur J Neurol; 2007 Feb; 14(2):168-73. PubMed ID: 17250725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.
    Brew BJ; Pemberton L; Blennow K; Wallin A; Hagberg L
    Neurology; 2005 Nov; 65(9):1490-2. PubMed ID: 16275845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
    Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
    J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
    Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
    Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF biomarkers in frontotemporal lobar degeneration with known pathology.
    Bian H; Van Swieten JC; Leight S; Massimo L; Wood E; Forman M; Moore P; de Koning I; Clark CM; Rosso S; Trojanowski J; Lee VM; Grossman M
    Neurology; 2008 May; 70(19 Pt 2):1827-35. PubMed ID: 18458217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different cerebrospinal fluid levels of Alzheimer-type biomarker Aβ42 between general paresis and asymptomatic neurosyphilis.
    Luo X; Shi H; Hou L; Zhong X; Chen X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chen J; Fang Y; He H; Ning Y
    Eur J Neurol; 2015 May; 22(5):853-8. PubMed ID: 25707998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia.
    Santangelo R; Coppi E; Ferrari L; Bernasconi MP; Pinto P; Passerini G; Comi G; Magnani G
    J Alzheimers Dis; 2015; 43(4):1429-40. PubMed ID: 25201781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
    Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
    Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.
    Blasko I; Lederer W; Oberbauer H; Walch T; Kemmler G; Hinterhuber H; Marksteiner J; Humpel C
    Dement Geriatr Cogn Disord; 2006; 21(1):9-15. PubMed ID: 16244482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
    Wallin AK; Blennow K; Andreasen N; Minthon L
    Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Will CSF analysis become routine in people with memory complaints?
    Gauthier S
    Lancet Neurol; 2009 Jul; 8(7):595-6. PubMed ID: 19523878
    [No Abstract]   [Full Text] [Related]  

  • 38. Cerebrospinal fluid biomarkers of neurodegeneration in patients with juvenile and classic myotonic dystrophy type 1.
    Peric S; Mandic-Stojmenovic G; Markovic I; Stefanova E; Ilic V; Parojcic A; Misirlic-Dencic S; Ostojic M; Rakocevic-Stojanovic V; Kostic V
    Eur J Neurol; 2014 Feb; 21(2):231-7. PubMed ID: 23834502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
    Wang ML; Wei XE; Yu MM; Li PY; Li WB;
    Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B; Bibl M; Wiltfang J; Steinacker P; Ciesielczyk B; Neubert K; Trenkwalder C; Otto M
    Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.